Jiangxi Puzhuo Medical Equipment Co., Ltd

At the invitation of Yingpuzhuo Medical, a team led by Cameron Higgins, a researcher at the University of Sydney and the Queensland Institute of Medical Research (QIMR Berghofer), a postdoctoral researcher at the Oxford Human Brain Activity Research Institute (OHBA), and the founder of Resonait, visited Nanchang, Jiangxi Province, for a two-day academic exchange and industrial cooperation inspection..

Puzhuo Medical and Resonait have officially established a partnership. The two parties will jointly explore the clinical application of non-invasive brain-computer interface in the field of mental and neurological diseases, and promote the transition of precision neural regulation technology from the laboratory to the clinical bedside.

Clinical research: stepping into the front line to perceive real needs

During his visit, Dr. Higgins visited Beijing Anding Hospital, Peking University Sixth Hospital, Beijing Zhongguancun Hospital, Jiangxi Provincial People's Hospital, and Ganjiang New Area People's Hospital in succession, gaining insights into the current situation and pain points of clinical diagnosis and treatment of depression in China. He proposed a precise adaptation neural regulation scheme based on brain network algorithms, laying a foundation for future clinical cooperation and expansion.

Academic discussion: Colliding ideas, colluding technological paths

Puzhuo Medical Academic Exchange Meeting

At Jiangxi Puzhuo Medical Co., Ltd., expert directors from Nanchang First Hospital, Jiangxi Provincial Mental Health Center, Jiangxi Provincial People's Hospital, and other institutions conducted an in-depth technical exchange symposium with the Resonait team in the company's conference room.

Both parties engaged in discussions regarding the underlying algorithms of the precision neural regulation product and its clinical applications, and reached a preliminary consensus.

Policy advocacy: The industrial ambitions of Ganjiang New Area

During the visit, Wang Wanzheng, Deputy Secretary of the Party Working Committee and Director of the Management Committee of Ganjiang New Area, extended a warm welcome to Dr. Cameron Higgins. Xiong Ying, Deputy Director of the Innovation and Development Bureau of Ganjiang New Area, participated in and organized the visit to the Jiangxi Medical Device Testing Center and Jiangxi Brain Valley-BCI Joint Innovation Center throughout the entire process

After the visit, Ganjiang New Area organized an industry symposium.

Wang Wanzheng, Deputy Secretary of the Party Working Committee and Director of the Management Committee of Ganjiang New Area, presided over the meeting, with Song Kaimei, Deputy Director of the Comprehensive Administrative Law Enforcement Bureau of Ganjiang New Area, and Xiong Ying, Deputy Director of the Innovation and Development Bureau, participating in the meeting. Dr. Cameron Higgins and representatives from Puzhuo Medical also attended the meeting.

During the symposium, the leaders of Ganjiang New Area introduced to Dr. Cameron Higgins the supportive policies of Ganjiang New Area for the brain-computer interface industry, and expressed their ardent hopes for future international exchanges and cooperation, jointly facilitating the establishment and growth of brain-computer interface technology in China.

Summary and Outlook

This two-day trip to Jiangxi is another substantial promotion of Puzhuo Medical's international cooperation and local industry collaboration, implementing multiple key links from technology verification to industrial landing one by one.

From the policy highland of Ganjiang New Area to the clinical front line, from the industrial forefront of BCI Joint Innovation Center to the cooperation consensus of the tripartite roundtable - Puzhuo Medical is building an efficient pathway connecting international cutting-edge technology with domestic market demand based on local clinical resources and industrial networks.

With the continuous promotion of the tripartite cooperation, Puzhuo Medical will continue to play a pivotal role in promoting precise neural regulation technology from the laboratory to clinical applications, bringing more valuable solutions to patients with mental and neurological disorders in China and even globally.